Opportunity to Acquire a Pioneering Health-Tech Innovator

Project Axon

Business Opportunity

• Opportunity to acquire a pre-revenue pioneering med-tech (device) business that has developed ML-powered technology to diagnose and monitor neuro impairments.
• The business has been incorporated for over 15 years and has benefitted from both academic support and the support from specialists in the neurosciences field.
• With ageing populations in the EU and US and the increasing prevalence of neurological impairments, it is considered that there is a potential significant requirement for the Company’s products in these markets.
• In addition to the Company’s technology, other key assets comprise of various domain names, trademark (UK) and a Patent held for the concept for the Company’s key product to diagnose neuro impairment. The patent is registered in many countries including but not limited to USA, Japan and many European countries including but not limited to Germany, France, UK, Italy, Switzerland and Spain.
• The technology combines sensor technology, digital biomarkers, and decision-support algorithms for quantification of function, providing results within minutes following a 15-minute test.

Business Highlights

• Tested on 250 subjects across leading European clinics.
• Global demand for early, accurate diagnosis of neurodegenerative conditions.
• Potential to streamline care pathways, reduce other costly processes and improve patient experience.
• The business benefits from the knowledge of a very well experienced CEO, CFO and CTO along with non-executive directors and other advisers.

Current Position

• The business has already successfully raised $10.5m in funding which was via a mixture of grants and investments.
• Class 1 registered in EU and class 2 in US for (non-disease specific) – exempt from review. Further investment is required to obtain additional approvals in the US ahead of launch in diagnosing and monitoring of neurodegenerative diseases.
• Further investment of approximately $5 million is still required for US trials and diagnostic approvals; another $16 million for US commercial launch.
• Whilst significant funding is still required, it is considered that this is a fantastic opportunity for an acquirer to access a multi-billion $ global market for neurological issues and care.